Purpose: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and
interferon alfa-2b (IFN-2b) in multiagent chemotherapy (CT) for advanced melanoma …

Background Based on phase II trial results, chemoimmunotherapy combinations have
become the preferred treatment for patients with metastatic melanoma in many institutions …

BACKGROUND The objective of the current study was to evaluate the response rate,
survival, and toxicity of treatment with cisplatin and high dose intravenous continuous …

Background: The addition of cytokines to chemotherapy (CT) has obtained encouraging but
contradictory results in metastatic melanoma. In this phase III trial, we compared the effects …

BACKGROUND In a previous study, the authors tested the combination of fotemustine (FM)
100 mg/m2 intravenously (iv) on Day 1, dacarbazine (DTIC) 250 mg/m2 iv on Days 2–5, and …

Both chemotherapy and interleukin-2 and/or interferon-α produce objective responses in a
proportion of advanced malignant melanoma patients. While duration of response to …

PURPOSE: The Cytokine Working Group performed a randomized phase II trial of two
outpatient biochemotherapy regimens to identify an outpatient regimen with high antitumor …

Background The safety and efficacy of immunotherapy with histamine dihydrochloride
(HDC), interleukin-2 (IL-2) and interferon-α2b (IFN) compared with dacarbazine (DTIC) in …

This randomized phase II study was designed to compare the efficacy and tolerability of
dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with …

The purpose of this study was to evaluate in a randomized phase II trial the efficacy and
toxicity of combination biochemotherapy compared with chemotherapy alone in patients with …